

# **Epidermal Growth Factor-like Protein 7 Monoclonal Antibody**

#### ORDERING INFORMATION

Catalog No.: 90013 (clone 2H2)
Format: 100ug, Protein A-purified,
lyophilized, 0.1M Tris, 0.1M glycine, 2%

sucrose, 1mg/ml.

## **BACKGROUND**

EGF-L7 (Epidermal Growth Factor Like Protein 7) is a multi-domain protein containing two EGF like domains and one EMI domain. It is expressed almost exclusively in endothelial cells and functions to promote normal development of the vascular system. EGF-L7 is capable of antagonistic binding to Notch receptors resulting in the inhibition of Notch signaling in HUVEC and neural stem cells. In research models inducing hypoxia and subsequent reoxygenation, (H/R), EGF-L7 can inhibit ICAM-1 expression and enhance the inhibition of NF-kappaB activation. Additionally, EGF-L7 is a chemoattractant for endothelial cells and binds to the extracellular matrix. The overexpression of EGF-L7 is observed in various cancers, and is generally correlated with increased metastasis and a poor prognosis.

### **SPECIFICATION SUMMARY**

**Antigen:** His-tagged EGFL-7 recombinant protein. Accession no. Q9UHF1.

Host species: Mouse. Antibody Class: IgG1. Preservative: None.

#### SPECIFICITY

This antibody reacts with human EGFL-7 protein.

#### <u>APPLICATIONS</u>

ELISA: use at 1-10ug/ml.

Immunoblotting: use at 1-5ug/ml. A
band of ~30kDa is detected.

Immunohistochemistry: Use at 2-

10ug/ml.

These are recommended concentrations. Enduser should determine optimal concentrations for their applications.

#### **RECONSTITUTION**

Reconstitute in distilled water.

# STORAGE AND STABILITY

This product is stable for at least one (1) year at -20°C to -70°C. Reconstituted product should be stored in appropriate aliquots to avoid repeated freeze-thaw cycles.

For in vitro investigational use only. Not for use in therapeutic or diagnostic procedures.